Navigation Links
CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer
Date:2/27/2009

PALO ALTO, Calif., Feb. 27 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today advised its stockholders to take no action at this time in response to Astellas Pharma Inc.'s announcement that its indirect subsidiary, Sturgeon Acquisition, Inc., has commenced an unsolicited tender offer for all outstanding common shares of CV Therapeutics at a price of $16.00 per share in cash.

CV Therapeutics' board of directors, in consultation with its independent financial and legal advisors, intends to advise stockholders of its formal position regarding the offer within 10 business days by filing a solicitation/recommendation statement on Schedule 14D-9 with the Securities and Exchange Commission and made available to stockholders.

Barclays Capital and Goldman Sachs are serving as financial advisors, and Latham & Watkins LLP is serving as legal counsel, to CV Therapeutics.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Europe Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina, and Lexiscan(R) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Ranexa(R) (ranolazine prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who a
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... A mechanised blue dye test alternative is help... assurance one step closer for pharma-companies. I... machine developed by Sepha for use with blister...l local and global pharma-companies such as Sanofi...ance and productivity improvements on the packagin...
(Date:11/25/2009)...ON,Fla.,Nov.25/PRNewswire/--Formanybusinesses,2009...slargestandfastestgrowingnetworkofexpertphysicians...enticalhormones has grownthenumberof physiciansi...ns -andisinprogresstoaddmorephysician-ownedcenters..., Inthepastyear ,BodyLogicMDhasopened13newbioident...
(Date:11/24/2009)...able in German . , Whether it,s CD packagin...Radio Frequency Identification) are increasingly f...possible to label objects or goods and identify th...te scanner can read and process the data contained...s under production conditions of up to 100 degrees...
(Date:11/24/2009)...IM,Ontario,Nov.24/PRNewswire-FirstCall/--DowAgroSc...HylandSeeds,adivisionofThompsonsLimitedofBlenheim,...owAgroSciences,currentseedsbusinessasthecompanyant...andDowAgroSciencesHerbicideTolerantTraitTechnology...earfuture. ,, "Thisacquisitionbringstogethertwo...
Breaking Biology Technology:Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 2Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance 3Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Intelligence inside metal components 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3
...signed to develop,educational opportunities for st...Tiger Woods Learning Center (TWLC) are collaborati.... "A recent report by the National,Research Counci...gued that,students are more likely to have increas...ipate in hands-on experiences," says Jeff Harford,...
...ticals,Inc. (OTCBB: ORMP.OB) ( http://www.oramed.c...ced today that it has been selected to display its...acodynamics (PD) of Oral Insulin in,Healthy Subjec...Association,s Scientific Sessions Conference in Sa...rom its oral insulin trials on healthy volunteers....
... numerous,shareholder questions, CEL-SCI CORPORATI...struction of its manufacturing facility near Balti... will comprise 73,000 square,feet and will be used...ancer product. This dedicated facility will produc...votal Phase III clinical trial for first-line,ther...
Other Biology Technology:LI-COR(R) Biosciences and Tiger Woods Learning Center Collaborate to Develop High School Curriculum in Genetics 2Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco) 2Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco) 3CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter 2CEL-SCI CORPORATION Manufacturing Facility for Pivotal Phase III Cancer Trial Scheduled to Be Completed During 2008 Third Quarter 3
(Date:11/26/2009)...istant Staphylococcus Aureus ) and other drug-res...perature plasma prototype devices have been develo...ricidal cocktails. , Two prototype devices have ...healthy skin (e.g. hands and feet) in hospitals an...hreat; and another to shoot bacteria-killing agent...
(Date:11/25/2009)...Head of the Cell Death Research Laboratory in the ...een awarded the prestigious Johnson & Johnson Focu...ause of brain cell damage in Parkinson,s disease. ...s in support of innovation and excellence in scien...d earlier this month at an event at the Hyatt Rege...
(Date:11/24/2009)...s it has been prescribed by traditional healers in...s and stomach pain to fever and flu. , Now for th...have been able to scientifically prove the pain re...known as Brazilian mint. , Testing this ancient S...cher Graciela Rocha was able to show that when pre...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Got a pain? -- Have a cup of Brazilian mint 2Locate a Male Menopause Physician with reNEW MAN 59257 1Locate a Male Menopause Physician with reNEW MAN 59257 2Locate a Male Menopause Physician with reNEW MAN 59257 3Locate a Male Menopause Physician with reNEW MAN 59257 4Discrete Reportable Transcription to Populate the EHR EMR With Physician Dictated Reports 59255 1Discrete Reportable Transcription to Populate the EHR EMR With Physician Dictated Reports 59255 2Discrete Reportable Transcription to Populate the EHR EMR With Physician Dictated Reports 59255 3How should mental neurological and substance use disorders be treated where resources are scarce 3F 59254 1How should mental neurological and substance use disorders be treated where resources are scarce 3F 59254 2
...versity of New Hampshire (UNH) have found that inv...ange in blue mussels in as little as 15 years. The... associate professor of zoology James Byers and pu...e, indicates that such a response can evolve in an... of years previously assumed. The paper is called ...
... by the United Nations shows the need for an inter...estructive fishing practices that damage deep sea ... U.N. Division for Ocean Affairs and Law of the Se...able deep oceans of the high seas ?the 64 percent ...ns of any individual nation. Its review, ordered b...
...e Children,s Research Hospital have announced that...one antigenic variant of the avian influenza virus...f the virus. Vaccines based on this model might th... a pandemic (worldwide epidemic) until a new vacci...iant causing the outbreak, the researchers said. A...
Other Biology News:Mussels evolve quickly to defend against invasive crabs 2Mussels evolve quickly to defend against invasive crabs 3UN review shows need to halt destructive fishing practice 2Scientists to employ Arctic ice and polar bears to protect diversity of world's crops 2
...croarrays are derived from Paraffin embedded tissu...control procedures to ensure the highest quality. ...e block, sectioned at a thickness of 5 microns and... mm in diameter) in comparison to core sections ma...
...croarrays are derived from Paraffin embedded tissu...control procedures to ensure the highest quality. ...e block, sectioned at a thickness of 5 microns and...mm in diameter) in comparison to core sections mad...
...pticon real-time PCR detection system uses a fixed...5 nm) and a photomultiplier tube for fluorescence ...t on an DNA Engine thermal cycler base, which incl...s the thermal cycler, 96-well sample block, optica...
...ned for Optimal Microdissection , CapSure HS and ...d extraction of populations of pure cells from tis...re Microdissection., Ensure the Integrity of Mic...s , All CapSure LCM Caps have a patented transfer...
Biology Products: